Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Bicycle Therapeutics plcNASDAQ: BCYC

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 11.8% from a year ago

Net receivables stood at $40.92M at the end of Q1 FY2026, down 11.8% from a year earlier and up 15.0% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Net receivables amounted to 6.3% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -11.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$40.92M+15.0% QoQ
Last fiscal yearDec 2025
$35.59M-0.2% YoY
Year agoMar 2025
$46.37M-11.8% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.8%——
1 year-0.2%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
35.59M USD
Year-over-year change
-0.2%
4-year CAGR
+31.5%

Net Receivables vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's Mar 2026 net receivables of $40.92M is the highest of the 10 companies compared; the peer median is $1.78M.
  • Its year-over-year change of -11.8% is the 3rd highest of 5, against a peer median of -16.2%.
  • Net receivables amounts to 6.3% of total assets for BCYC, versus a peer median of 0.5%.
BCYC Competitors Peer median
Net Receivables for BCYC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BCYCBicycle Therapeutics plcMar 2026$40.92M -11.8%+18.8%6.3%
OMEROmeros CorporationMar 2026$37.51M +566.5%-46.9%13.1%
ADCTADC Therapeutics S.A.Mar 2026$31.05M -2.3%-26.4%10.7%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$11.78M -75.2%+339.9%4.4%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$11.3M ——3.4%
FULCFulcrum Therapeutics, Inc.Mar 2026$1.78M -30.1%-0.3%0.5%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$0 ——0.0%
PRTAProthena Corporation plcMar 2026$0 ——0.0%
CMPXCompass Therapeutics, Inc.Mar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding BCYC) $1.78M-16.2%-13.4%0.5%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents438.68M339.15M526.42M879.52M628.11M
Short-term Investments00000
Net Receivables11.91M21.21M24.04M35.65M35.59M
Inventory00000
Other Current Assets7.97M9.02M11.41M13.43M(35.59M)
Total Current Assets458.56M369.38M561.87M928.61M628.11M
Property, Plant & Equipment (Net)17.79M32.77M27.68M17.19M21.91M
Goodwill00000
Intangible Assets00000
Long-term Investments00547K547K58K
Tax Assets00000
Other Non-current Assets3.45M8.46M5.24M10.53M12.75M
Total Non-current Assets21.24M41.23M33.48M28.26M34.71M
Total Assets479.79M410.61M595.34M956.87M717.6M
Account Payables2.72M6.47M13.05M15.79M9.67M
Short-term Debt004.88M02.76M
Tax Payables00000
Deferred Revenue19.27M20.42M24.98M10.19M2.96M
Other Current Liabilities7M13.4M13.24M16.57M17.14M
Total Current Liabilities36.24M53.34M69.54M67.23M56.98M
Long-term Debt29.87M30.32M30.7M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)52.07M41.46M110.22M91.47M35.51M
Other Non-current Liabilities3.28M3.83M4.58M1.12M363K
Total Non-current Liabilities97.3M86.48M154.88M96.58M50.64M
Total Liabilities133.54M139.83M224.41M163.81M107.62M
Common Stock384K387K550K890K894K
Retained Earnings(218.38M)(331.1M)(511.76M)(680.79M)(899.75M)
Accumulated OCI(3.39M)387K(1.3M)119K(3.51M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity346.25M270.78M370.93M793.06M609.98M
Total Debt44.34M44.33M44.96M9.49M17.52M
Net Debt(394.34M)(294.83M)(481.47M)(870.03M)(610.59M)

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.